

Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service (Regulatory Consulting), By Phase (Preclinical), By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2024 - 2030

<https://marketpublishers.com/r/BE3085E17BA4EN.html>

Date: July 2024

Pages: 120

Price: US\$ 5,950.00 (Single User License)

ID: BE3085E17BA4EN

Abstracts

This report can be delivered to the clients within 2 Business Days

Biologics Regulatory Affairs Outsourcing Market Growth & Trends

The global biologics regulatory affairs outsourcing market size is expected to reach USD 3.69 billion by 2030, registering a CAGR of 8.87% from 2024 to 2030, according to a new report by Grand View Research, Inc. Globalization of biopharmaceutical companies is one of the major growth drivers boosting overall market demand. Emerging markets of Asia Pacific, Latin America, and MEA regions offer low product development & manufacturing costs, tax benefits, and availability of skilled labor at relatively low costs with supportive regulations. The abovementioned factors have made the regional markets attractive prospects in terms of outsourcing and expansion for biopharmaceutical companies, thereby stimulating the demand for regulatory services. Furthermore, the presence of EMA- and/or FDA-approved facilities in emerging economies is anticipated to increase foreign investments in the country and the demand for regulatory services, such as legal representation and regulatory consulting services.

A significant increase has been witnessed in the number of clinical trials conducted in emerging economies. This can be attributed to the availability of skilled labor,

advanced technologies, and infrastructure facilities at relatively lower costs than developed economies such as the U.S., which is expected to stimulate the demand for regulatory services such as clinical trial applications & product registrations in these regions. Emerging economies contribute more than 30.0% of total clinical trial applications submitted across the globe, and the share is expected to increase over the coming years, contributing to market growth.

Several biopharmaceutical companies are focusing on their core competencies and outsourcing noncore functions to increase their productivity & operational efficiency. These companies face several challenges with regard to complying with global regulations, which can be a lengthy and tedious process. Thus, the race to launch a novel molecule in the market in a feasible timeline and at a reasonable cost will likely propel the demand for service providers. Furthermore, many small- and medium-scale biopharma companies lacking in-house capabilities are inclined towards outsourcing regulatory affairs, which is estimated to positively influence the industry's progression.

Growth in markets for biosimilars, orphan drugs, personalized medicines, adaptive trial designs, and others is projected to boost the demand for regulatory specialization in these areas. As several companies expand into new avenues, the increasing need for skilled service providers with experience in regulations leads to the necessity to comply with regulations. Government support, especially in developed economies, has significantly increased the development of orphan drugs. Patent expiration of biologics, such as Simlect, Vectibix, Mircera, and Kineret, is increasing the demand and development of biosimilars, thereby contributing to the demand for regulatory services in this segment.

Biologics Regulatory Affairs Outsourcing Market Report Highlights

The regulatory writing & publishing segment held the largest market share in 2023. The high segment growth is owing to the increasing complexity of biologics requiring precise and comprehensive documentation, stringent global regulatory requirements demanding thorough submissions, and the need for specialized expertise to ensure compliance. The rapid pace of innovation in biologics, such as gene therapies and biosimilars, necessitates up-to-date knowledge of evolving regulations is anticipated overall market growth

The pharmaceutical companies segment accounted for the largest revenue share of over 76.23% in 2023. The segmental growth is owing to a high number of clinical trials for biologics, a growing product pipeline for ATMPs, stringent regulatory guidelines for advanced therapeutics, and growing outsourcing trends for non-core activities such as clinical trials, data management, regulatory compliance etc., are few factors further boosting segment growth

The monoclonal antibodies (mAbs) segment accounted for the largest revenue share in 2023. The segmental growth is owing to rapid advancements in mAb technology, including novel delivery methods and therapeutic targets, which require updated and precise regulatory strategies leading to overall market growth potential

North America dominated the market with a share of 30.54% in 2023. The regional market growth is owing to high R&D activities and government initiatives for clinical trials. Moreover, the strong presence of biopharmaceutical companies and outsourcing service providers is another major factor expected to propel market growth. For instance, in October 2021, the U.S. FDA approved 11 novel clinical trial research, resulting in over USD 25 million in funding over the next four years to support the development of innovative drugs to treat rare diseases

Contents

CHAPTER 1. METHODOLOGY AND SCOPE

- 1.1. Market Segmentation & Scope
 - 1.1.1. Regional Scope
 - 1.1.2. Estimates and Forecast Timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
 - 1.3.1. Purchased Database
 - 1.3.2. GVR's Internal Database
 - 1.3.3. Secondary Sources
 - 1.3.4. Primary Research
- 1.4. Information or Data Analysis
 - 1.4.1. Data Analysis Models
- 1.5. Market Formulation & Validation
 - 1.5.1. Region Wise Market: Base Estimates
 - 1.5.2. Global Market: CAGR Calculation
- 1.6. Model Details
 - 1.6.1. Commodity Flow Analysis (Model 1)
 - 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
 - 1.6.3. QFD Model Sizing & Forecasting (Model 3)
 - 1.6.4. Bottom-Up Approach (Model 4)
- 1.7. Market Definitions
- 1.8. List of Secondary Sources
- 1.9. List of Abbreviations
- 1.10. Objectives
 - 1.10.1. Objective - 1:
 - 1.10.2. Objective - 2:
 - 1.10.3. Objective - 3:
 - 1.10.4. Objective - 4:

CHAPTER 2. EXECUTIVE SUMMARY

- 2.1. Market Outlook
- 2.2. Segment Outlook
 - 2.2.1. Service Outlook
 - 2.2.2. Phase Outlook
 - 2.2.3. Modality Outlook

- 2.2.4. Phase by Service Outlook
- 2.2.5. Phase by Modality Outlook
- 2.2.6. Modality by Service Outlook
- 2.2.7. Regional Outlook
- 2.3. Competitive Insights

CHAPTER 3. BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET VARIABLES, TRENDS & SCOPE

- 3.1. Market Lineage Outlook
 - 3.1.1. Parent Market Outlook
 - 3.1.2. Ancillary Market Outlook
- 3.2. Market Dynamics
 - 3.2.1. Market Driver Analysis
 - 3.2.1.1. Growing Number of Clinical Trials
 - 3.2.1.2. Increasing Adoption of the Personalized Medicine and Novel Therapeutics
 - 3.2.1.3. Rising R&D Investment in the Healthcare Industry
 - 3.2.1.4. Advancements in the Regulatory Affairs Market
 - 3.2.2. Market Restraint Analysis
 - 3.2.2.1. Compliance Issues While Outsourcing
 - 3.2.2.2. Managing Relationships
- 3.3. Technological Advancements
 - 3.3.1. Existing and Emerging Use of Technology and Preferred Tools
 - 3.3.2. Differentiating In-House Tools Vs Widely Available
 - 3.3.3. Key Technology Pillars
 - 3.3.3.1. Digital Transformation and Data Integrity
 - 3.3.3.2. Artificial Intelligence, Machine Learning/Automation
 - 3.3.3.3. Data Analysis and Predictive Modeling
 - 3.3.3.4. Automation of Routine Tasks
 - 3.3.3.5. Compliance Monitoring
 - 3.3.3.6. Discovery and Development
 - 3.3.3.7. Regulatory Guidelines Related to AI/ML
 - 3.3.4. Big Data and Analytics
 - 3.3.5. RTP, Text Processing and Analytics
 - 3.3.6. Speech and Video Analytics
 - 3.3.7. IoT (Internet Of Things)
 - 3.3.8. AI Tools
- 3.4. Pricing Model Analysis
- 3.5. Clinical Trials Volume Analysis, 2023

- 3.5.1. Total Number of Clinical Trials, by Region (2023)
- 3.5.2. Total Number of Clinical Trials, by Phase (2023)
- 3.5.3. Total Number of Clinical Trials, by Study Design (2023)
- 3.5.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
- 3.6. Biologics Regulatory Affairs Outsourcing Market: Analysis Tools
 - 3.6.1. Porter's Five Forces Analysis
 - 3.6.2. PESTEL Analysis
- 3.7. COVID-19 Impact Analysis

CHAPTER 4. BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET: SERVICE ESTIMATES & TREND ANALYSIS

- 4.1. Segment Dashboard
- 4.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis
- 4.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
 - 4.3.1. Regulatory Consulting
 - 4.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 4.3.1.2. Strategy & Development Planning
 - 4.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 4.3.1.3. QA Consulting
 - 4.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 4.3.1.4. Agent Services
 - 4.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 4.3.1.5. Others
 - 4.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 4.3.2. Legal Representation
 - 4.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 4.3.3. Regulatory Writing & Publishing
 - 4.3.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 4.3.4. Product Registration & Clinical Trial Applications
 - 4.3.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 4.3.5. Regulatory Submissions
 - 4.3.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 4.3.6. Regulatory Operations
 - 4.3.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 4.3.7. Other Services
 - 4.3.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

CHAPTER 5. BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET: PHASE ESTIMATES & TREND ANALYSIS

5.1. Segment Dashboard

5.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis

5.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)

5.3.1. Preclinical

5.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

5.3.2. Clinical

5.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

5.3.2.2. Phase I

5.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

5.3.2.3. Phase II

5.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

5.3.2.4. Phase III

5.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

5.3.2.5. Phase IV

5.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

CHAPTER 6. BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET: MODALITY ESTIMATES & TREND ANALYSIS

6.1. Segment Dashboard

6.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis

6.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, by Modality, 2018 to 2030 (USD Million)

6.4. Monoclonal Antibodies (mAbs)

6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

6.5. Recombinant Proteins

6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

6.6. Vaccines

6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

6.7. Cell & Gene Therapies

6.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

6.8. Biosimilars

6.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

6.9. Others

6.9.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

CHAPTER 7. BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET: PHASE BY SERVICE ESTIMATES & TREND ANALYSIS

7.1. Segment Dashboard

7.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis

7.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Phase by Service, 2018 to 2030 (USD Million)

7.3.1. Preclinical

7.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.1.2. Regulatory Consulting

7.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.1.3. Legal Representation

7.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.1.4. Regulatory Writing & Publishing

7.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.1.5. Product Registration & Clinical Trial Applications

7.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.1.6. Regulatory Submissions

7.3.1.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.1.7. Regulatory Operations

7.3.1.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.1.8. Other Services

7.3.1.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.2. Clinical

7.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.2.2. Regulatory Consulting

7.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.2.3. Legal Representation

7.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.2.4. Regulatory Writing & Publishing

7.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.2.5. Product Registration & Clinical Trial Applications

7.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.2.6. Regulatory Submissions

7.3.2.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.2.7. Regulatory Operations

7.3.2.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

7.3.2.8. Other Services

7.3.2.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

CHAPTER 8. BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET: PHASE BY MODALITY ESTIMATES & TREND ANALYSIS

8.1. Segment Dashboard

8.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis

8.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Phase by Modality, 2018 to 2030 (USD Million)

8.3.1. Preclinical

8.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.1.2. Monoclonal Antibodies (mAbs)

8.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.1.3. Recombinant Proteins

8.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.1.4. Vaccines

8.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.1.5. Cell & Gene Therapies

8.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.1.6. Biosimilars

8.3.1.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.1.7. Others

8.3.1.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.2. Clinical

8.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.2.2. Monoclonal Antibodies (mAbs)

8.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.2.3. Recombinant Proteins

8.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.2.4. Vaccines

8.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.2.5. Cell & Gene Therapies

8.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.2.6. Biosimilars

8.3.2.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

8.3.2.7. Others

8.3.2.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

CHAPTER 9. BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET:

MODALITY BY SERVICE ESTIMATES & TREND ANALYSIS

9.1. Segment Dashboard

9.2. Global Biologics Regulatory Affairs Outsourcing Market Movement Analysis

9.3. Global Biologics Regulatory Affairs Outsourcing Market Size & Trend Analysis, Modality by Service, 2018 to 2030 (USD Million)

9.3.1. Monoclonal Antibodies (mAbs)

9.3.1.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.1.2. Regulatory Consulting

9.3.1.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.1.3. Legal Representation

9.3.1.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.1.4. Regulatory Writing & Publishing

9.3.1.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.1.5. Product Registration & Clinical Trial Applications

9.3.1.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.1.6. Regulatory Submissions

9.3.1.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.1.7. Regulatory Operations

9.3.1.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.1.8. Other Services

9.3.1.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.2. Recombinant Proteins

9.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.2.2. Regulatory Consulting

9.3.2.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.2.3. Legal Representation

9.3.2.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.2.4. Regulatory Writing & Publishing

9.3.2.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.2.5. Product Registration & Clinical Trial Applications

9.3.2.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.2.6. Regulatory Submissions

9.3.2.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.2.7. Regulatory Operations

9.3.2.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.2.8. Other Services

9.3.2.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

9.3.3. Vaccines

- 9.3.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.3.2. Regulatory Consulting
 - 9.3.3.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.3.3. Legal Representation
 - 9.3.3.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.3.4. Regulatory Writing & Publishing
 - 9.3.3.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.3.5. Product Registration & Clinical Trial Applications
 - 9.3.3.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.3.6. Regulatory Submissions
 - 9.3.3.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.3.7. Regulatory Operations
 - 9.3.3.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.3.8. Other Services
 - 9.3.3.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.4. Cell & Gene Therapies
 - 9.3.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.4.2. Regulatory Consulting
 - 9.3.4.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.4.3. Legal Representation
 - 9.3.4.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.4.4. Regulatory Writing & Publishing
 - 9.3.4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.4.5. Product Registration & Clinical Trial Applications
 - 9.3.4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.4.6. Regulatory Submissions
 - 9.3.4.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.4.7. Regulatory Operations
 - 9.3.4.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.4.8. Other Services
 - 9.3.4.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.5. Biosimilars
 - 9.3.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.5.2. Regulatory Consulting
 - 9.3.5.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.5.3. Legal Representation
 - 9.3.5.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.5.4. Regulatory Writing & Publishing
 - 9.3.5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

- 9.3.5.5. Product Registration & Clinical Trial Applications
 - 9.3.5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.5.6. Regulatory Submissions
 - 9.3.5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.5.7. Regulatory Operations
 - 9.3.5.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.5.8. Other Services
 - 9.3.5.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 9.3.6. Others
 - 9.3.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.6.2. Regulatory Consulting
 - 9.3.6.2.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.6.3. Legal Representation
 - 9.3.6.3.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.6.4. Regulatory Writing & Publishing
 - 9.3.6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.6.5. Product Registration & Clinical Trial Applications
 - 9.3.6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.6.6. Regulatory Submissions
 - 9.3.6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.6.7. Regulatory Operations
 - 9.3.6.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 9.3.6.8. Other Services
 - 9.3.6.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)

CHAPTER 10. BIOLOGICS REGULATORY AFFAIRS OUTSOURCING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS

- 10.1. Regional Market Dashboard
- 10.2. Global Regional Market Snapshot
- 10.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 10.4. North America
 - 10.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.4.2. U.S.
 - 10.4.2.1. Key Country Dynamics
 - 10.4.2.2. Competitive Scenario
 - 10.4.2.3. Regulatory Scenario
 - 10.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.4.3. Canada

- 10.4.3.1. Key Country Dynamics
- 10.4.3.2. Competitive Scenario
- 10.4.3.3. Regulatory Scenario
- 10.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.4.4. Mexico
 - 10.4.4.1. Key Country Dynamics
 - 10.4.4.2. Competitive Scenario
 - 10.4.4.3. Regulatory Scenario
 - 10.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5. Europe
 - 10.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.5.2. UK
 - 10.5.2.1. Key Country Dynamics
 - 10.5.2.2. Competitive Scenario
 - 10.5.2.3. Regulatory Scenario
 - 10.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.5.3. Germany
 - 10.5.3.1. Key Country Dynamics
 - 10.5.3.2. Competitive Scenario
 - 10.5.3.3. Regulatory Scenario
 - 10.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.5.4. France
 - 10.5.4.1. Key Country Dynamics
 - 10.5.4.2. Competitive Scenario
 - 10.5.4.3. Regulatory Scenario
 - 10.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.5.5. Italy
 - 10.5.5.1. Key Country Dynamics
 - 10.5.5.2. Competitive Scenario
 - 10.5.5.3. Regulatory Scenario
 - 10.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.5.6. Spain
 - 10.5.6.1. Key Country Dynamics
 - 10.5.6.2. Competitive Scenario
 - 10.5.6.3. Regulatory Scenario
 - 10.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.5.7. Denmark
 - 10.5.7.1. Key Country Dynamics
 - 10.5.7.2. Competitive Scenario

- 10.5.7.3. Regulatory Scenario
- 10.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5.8. Sweden
 - 10.5.8.1. Key Country Dynamics
 - 10.5.8.2. Competitive Scenario
 - 10.5.8.3. Regulatory Scenario
 - 10.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.5.9. Norway
 - 10.5.9.1. Key Country Dynamics
 - 10.5.9.2. Competitive Scenario
 - 10.5.9.3. Regulatory Scenario
 - 10.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.6. Asia Pacific
 - 10.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.6.2. China
 - 10.6.2.1. Key Country Dynamics
 - 10.6.2.2. Competitive Scenario
 - 10.6.2.3. Regulatory Scenario
 - 10.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.6.3. Japan
 - 10.6.3.1. Key Country Dynamics
 - 10.6.3.2. Competitive Scenario
 - 10.6.3.3. Regulatory Scenario
 - 10.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.6.4. India
 - 10.6.4.1. Key Country Dynamics
 - 10.6.4.2. Competitive Scenario
 - 10.6.4.3. Regulatory Scenario
 - 10.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.6.5. Australia
 - 10.6.5.1. Key Country Dynamics
 - 10.6.5.2. Competitive Scenario
 - 10.6.5.3. Regulatory Scenario
 - 10.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.6.6. South Korea
 - 10.6.6.2. Competitive Scenario
 - 10.6.6.3. Regulatory Scenario
 - 10.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.6.7. Thailand

- 10.6.7.1. Key Country Dynamics
- 10.6.7.2. Competitive Scenario
- 10.6.7.3. Regulatory Scenario
- 10.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.7. Latin America
 - 10.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.7.2. Brazil
 - 10.7.2.1. Key Country Dynamics
 - 10.7.2.2. Competitive Scenario
 - 10.7.2.3. Regulatory Scenario
 - 10.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.7.3. Argentina
 - 10.7.3.1. Key Country Dynamics
 - 10.7.3.2. Competitive Scenario
 - 10.7.3.3. Regulatory Scenario
 - 10.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
- 10.8. MEA
 - 10.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.8.2. South Africa
 - 10.8.2.1. Key Country Dynamics
 - 10.8.2.2. Competitive Scenario
 - 10.8.2.3. Regulatory Scenario
 - 10.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.8.3. Saudi Arabia
 - 10.8.3.1. Key Country Dynamics
 - 10.8.3.2. Competitive Scenario
 - 10.8.3.3. Regulatory Scenario
 - 10.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.8.4. UAE
 - 10.8.4.1. Key Country Dynamics
 - 10.8.4.2. Competitive Scenario
 - 10.8.4.3. Regulatory Scenario
 - 10.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
 - 10.8.5. Kuwait
 - 10.8.5.1. Key Country Dynamics
 - 10.8.5.2. Competitive Scenario
 - 10.8.5.3. Regulatory Scenario
 - 10.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)

List Of Tables

LIST OF TABLES

1. List of Secondary Sources
2. List of Abbreviations
3. Global Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
4. Global Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
5. Global Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
6. Global Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
7. Global Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
8. Global Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
9. Global Biologics Regulatory Affairs Outsourcing, by Region, 2018 - 2030 (USD Million)
10. North America Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
11. North America Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
12. North America Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
13. North America Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
14. North America Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
15. North America Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
16. North America Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
17. U.S. Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
18. U.S. Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
19. U.S. Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

20. U.S. Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
21. U.S. Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
22. U.S. Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
23. Canada Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
24. Canada Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
25. Canada Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
26. Canada Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
27. Canada Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
28. Canada Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
29. Mexico Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
30. Mexico Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
31. Mexico Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
32. Mexico Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
33. Mexico Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
34. Mexico Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
35. Europe Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
36. Europe Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
37. Europe Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
38. Europe Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
39. Europe Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030

(USD Million)

40. Europe Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030

(USD Million)

41. Europe Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030

(USD Million)

42. Germany Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)

43. Germany Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)

44. Germany Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

45. Germany Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)

46. Germany Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)

47. Germany Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

48. UK Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)

49. UK Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)

50. UK Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

51. UK Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)

52. UK Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)

53. UK Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

54. France Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)

55. France Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)

56. France Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

57. France Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)

58. France Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)

59. France Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

60. Italy Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)

61. Italy Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
62. Italy Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
63. Italy Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
64. Italy Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
65. Italy Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
66. Spain Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
67. Spain Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
68. Spain Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
69. Spain Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
70. Spain Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
71. Spain Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
72. Denmark Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
73. Denmark Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
74. Denmark Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
75. Denmark Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
76. Denmark Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
77. Denmark Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
78. Sweden Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
79. Sweden Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
80. Sweden Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

81. Sweden Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
82. Sweden Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
83. Sweden Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
84. Norway Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
85. Norway Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
86. Norway Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
87. Norway Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
88. Norway Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
89. Norway Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
90. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
91. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
92. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
93. Asia Pacific Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
94. Asia Pacific Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
95. Asia Pacific Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
96. Asia Pacific Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
97. China Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
98. China Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
99. China Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
100. China Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030

(USD Million)

101. China Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030

(USD Million)

102. China Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030

(USD Million)

103. Japan Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)

104. Japan Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)

105. Japan Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

106. Japan Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)

107. Japan Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)

108. Japan Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

109. India Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)

110. India Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)

111. India Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

112. India Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)

113. India Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)

114. India Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

115. South Korea Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)

116. South Korea Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)

117. South Korea Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

118. South Korea Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)

119. South Korea Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)

120. South Korea Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
121. Australia Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
122. Australia Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
123. Australia Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
124. Australia Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
125. Australia Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
126. Australia Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
127. Thailand Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
128. Thailand Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
129. Thailand Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
130. Thailand Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
131. Thailand Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
132. Thailand Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
133. Latin America Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)
134. Latin America Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
135. Latin America Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
136. Latin America Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
137. Latin America Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
138. Latin America Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
139. Latin America Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

- 2030 (USD Million)

140. Brazil Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)

141. Brazil Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)

142. Brazil Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

143. Brazil Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)

144. Brazil Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)

145. Brazil Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

146. Argentina Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)

147. Argentina Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)

148. Argentina Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

149. Argentina Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)

150. Argentina Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)

151. Argentina Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

152. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Country, 2018 - 2030 (USD Million)

153. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)

154. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)

155. Middle East & Africa Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

156. Middle East & Africa Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)

157. Middle East & Africa Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)

158. Middle East & Africa Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

159. South Africa Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
160. South Africa Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
161. South Africa Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
162. South Africa Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
163. South Africa Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
164. South Africa Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
165. Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
166. Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
167. Saudi Arabia Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
168. Saudi Arabia Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
169. Saudi Arabia Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
170. Saudi Arabia Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
171. UAE Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
172. UAE Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)
173. UAE Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)
174. UAE Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)
175. UAE Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)
176. UAE Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)
177. Kuwait Biologics Regulatory Affairs Outsourcing, by Service, 2018 - 2030 (USD Million)
178. Kuwait Biologics Regulatory Affairs Outsourcing, by Phase, 2018 - 2030 (USD Million)

Million)

179. Kuwait Biologics Regulatory Affairs Outsourcing, by Modality, 2018 - 2030 (USD Million)

180. Kuwait Biologics Regulatory Affairs Outsourcing, Phase by Service, 2018 - 2030 (USD Million)

181. Kuwait Biologics Regulatory Affairs Outsourcing, Phase by Modality, 2018 - 2030 (USD Million)

182. Kuwait Biologics Regulatory Affairs Outsourcing, Modality by Service, 2018 - 2030 (USD Million)

List Of Figures

LIST OF FIGURES

- FIG. 1 Market segmentation
- FIG. 2 Information procurement
- FIG. 3 Data analysis models
- FIG. 4 Market formulation and validation
- FIG. 5 Data validating & publishing
- FIG. 6 Market snapshot
- FIG. 7 Segmental outlook - Material, Product, and Application
- FIG. 8 Competitive Outlook
- FIG. 9 Metal shim market outlook, 2018 - 2030 (USD Million)
- FIG. 10 Value chain analysis
- FIG. 11 Sales channel analysis
- FIG. 12 Market dynamics
- FIG. 13 Porter's Analysis
- FIG. 14 PESTEL Analysis
- FIG. 15 Metal shim market, by material: Key takeaways
- FIG. 16 Metal shim market, by material: Market share, 2023 & 2030
- FIG. 17 Metal shim market, by product: Key takeaways
- FIG. 18 Metal shim market, by product: Market share, 2023 & 2030
- FIG. 19 Metal shim market, by application: Key takeaways
- FIG. 20 Metal shim market, by application: Market share, 2023 & 2030
- FIG. 21 Metal shim market: Regional analysis, 2023
- FIG. 22 Metal shim market, by region: Key takeaways

I would like to order

Product name: Biologics Regulatory Affairs Outsourcing Market Size, Share & Trends Analysis Report By Service (Regulatory Consulting), By Phase (Preclinical), By Modality, Phase by Service, Phase by Modality, Modality by Service, By Region, And Segment Forecasts, 2024 - 2030

Product link: <https://marketpublishers.com/r/BE3085E17BA4EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BE3085E17BA4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970